Significant Reduction of Radiation-Induced Xerostomia in Head and Neck Cancer With Intensity Modulated Radiotherapy (IMRT) Compared to Conventional 3D-Conformal Radiotherapy (3D-CRT)

Author(s):  
M.R. Vergeer ◽  
P. Doornaert ◽  
D.H.F. Rietveld ◽  
A. Jellema ◽  
C.R. Leemans ◽  
...  
2016 ◽  
Vol 23 (3) ◽  
pp. 228 ◽  
Author(s):  
J.H.E Yong ◽  
T. McGowan ◽  
R. Redmond-Misner ◽  
J. Beca ◽  
P. Warde ◽  
...  

Background Radiotherapy is a common treatment for many cancers, but up-to-date estimates of the costs of radiotherapy are lacking. In the present study, we estimated the unit costs of intensity-modulated radiotherapy (IMRT) and 3-dimensional conformal radiotherapy (3D-CRT) in Ontario.Methods An activity-based costing model was developed to estimate the costs of IMRT and 3D-CRT in prostate cancer. It included the costs of equipment, staff, and supporting infrastructure. The framework was subsequently adapted to estimate the costs of radiotherapy in breast cancer and head-and-neck cancer. We also tested various scenarios by varying the program maturity and the use of volumetric modulated arc therapy (VMAT) alongside IMRT.Results From the perspective of the health care system, treating prostate cancer with IMRT and 3D-CRT respectively cost $12,834 and $12,453 per patient. The cost of radiotherapy ranged from $5,270 to $14,155 and was sensitive to analytic perspective, radiation technique, and disease site. Cases of head-and-neck cancer were the most costly, being driven by treatment complexity and fractions per treatment. Although IMRT was more costly than 3D-crt, its cost will likely decline over time as programs mature and VMAT is incorporated.Conclusions Our costing model can be modified to estimate the costs of 3D-CRT and IMRT for various disease sites and settings. The results demonstrate the important role of capital costs in studies of radiotherapy cost from a health system perspective, which our model can accommodate. In addition, our study established the need for future analyses of IMRT cost to consider how VMAT affects time consumption.


2006 ◽  
Vol 24 (17) ◽  
pp. 2618-2623 ◽  
Author(s):  
William M. Mendenhall ◽  
Robert J. Amdur ◽  
Jatinder R. Palta

The purpose of this article is to review the role of intensity-modulated radiotherapy (IMRT) in the standard management of patients with head and neck cancer through a critical review of the pertinent literature. IMRT may result in a dose distribution that is more conformal than that achieved with three-dimensional conformal radiotherapy (3D CRT), allowing dose reduction to normal structures and thus decreasing toxicity and possibly enhancing locoregional control through dose escalation. Disadvantages associated with IMRT include increased risk of a marginal miss, decreased dose homogeneity, increased total body dose, and increased labor and expense. Outcomes data after IMRT are limited, and follow-up is relatively short. Locoregional control rates appear to be comparable to those achieved with 3D CRT and, depending on the location and extent of the tumor, late toxicity may be lower. Despite limited data on clinical outcomes, IMRT has been widely adopted as a standard technique in routine practice and clinical trials. The use of IMRT involves a learning curve for the practitioner and will continue to evolve, requiring continuing education and monitoring of outcomes from routine practice. Additional standards pertaining to a variety of issues, including target definitions and dose specification, need to be developed. Phase III trials will better define the role of IMRT in coming years.


Sign in / Sign up

Export Citation Format

Share Document